Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
30.87
-0.18 (-0.58%)
At close: Dec 5, 2025, 4:00 PM EST
31.04
+0.17 (0.55%)
After-hours: Dec 5, 2025, 5:13 PM EST
Stoke Therapeutics Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Stoke Therapeutics stock ranges from a low of $24 to a high of $39. The average analyst price target of $31 forecasts a 0.42% increase in the stock price over the next year.
Price Target: $31.00 (+0.42%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 5, 2025.
Analyst Ratings
The average analyst rating for Stoke Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 6 | 6 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 7 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $24 → $28 | Strong Buy | Maintains | $24 → $28 | -9.30% | Nov 5, 2025 |
| Wedbush | Wedbush | Buy Maintains $22 → $32 | Buy | Maintains | $22 → $32 | +3.66% | Nov 5, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $39 | Strong Buy | Reiterates | $39 | +26.34% | Nov 5, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $15 → $25 | Hold | Maintains | $15 → $25 | -19.02% | Nov 3, 2025 |
| BTIG | BTIG | Strong Buy Maintains $28 → $39 | Strong Buy | Maintains | $28 → $39 | +26.34% | Oct 13, 2025 |
Financial Forecast
Revenue This Year
193.83M
from 36.56M
Increased by 430.24%
Revenue Next Year
34.88M
from 193.83M
Decreased by -82.00%
EPS This Year
0.16
from -1.65
EPS Next Year
-3.17
from 0.16
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 209.7M | 73.5M | ||||
| Avg | 193.8M | 34.9M | ||||
| Low | 182.3M | 11.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 473.6% | -62.1% | ||||
| Avg | 430.2% | -82.0% | ||||
| Low | 398.7% | -93.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.45 | -2.61 | ||||
| Avg | 0.16 | -3.17 | ||||
| Low | 0.02 | -3.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.